Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Covington
Johnson and Johnson
Mallinckrodt
Accenture
Fuji
Teva
Chinese Patent Office
Cerilliant
Harvard Business School

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,866,474

« Back to Dashboard

Which drugs does patent 7,866,474 protect, and when does it expire?

Patent 7,866,474 protects PRADAXA and is included in one NDA.

This patent has twenty-two patent family members in seventeen countries.
Summary for Patent: 7,866,474
Title:Film container
Abstract: A film container (FIG. 4) comprises two rectangular films (5) joined together at their periphery to form a receiving chamber (6) for a filling (7), particularly a pharmaceutical formulation of an active substance, at least one of said films (5) being provided, for the purpose of tearing it open, with a marking (13) formed within the connecting region, which is exposed after the films (5) have been bent. The marking (13) extends centrally between two opposing outer edges (11) of the film container (1).
Inventor(s): Geser; Johannes (Ingelheim, DE), Beyer; Sebastian (Eltville, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:11/305,365
Patent Claim Types:
see list of patent claims
Formulation; Composition;

Drugs Protected by US Patent 7,866,474

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate CAPSULE;ORAL 022512-001 Oct 19, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate CAPSULE;ORAL 022512-003 Nov 20, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate CAPSULE;ORAL 022512-002 Oct 19, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,866,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2004 062 864Dec 21, 2004

International Patents Family Members for US Patent 7,866,474

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 556336 ➤ Try a Free Trial
Norway 338848 ➤ Try a Free Trial
Norway 20072669 ➤ Try a Free Trial
Mexico 2007007464 ➤ Try a Free Trial
South Korea 101237768 ➤ Try a Free Trial
South Korea 20070094800 ➤ Try a Free Trial
Japan 4958902 ➤ Try a Free Trial
Japan 2008531428 ➤ Try a Free Trial
Israel 184086 ➤ Try a Free Trial
European Patent Office 2426064 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cantor Fitzgerald
US Army
Accenture
Mallinckrodt
Fuji
Healthtrust
Express Scripts
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot